<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="SARS-CoV-2 entry into the host cells, anti-androgenic agents, such as" exact="bicalutamide" post="and enzalutamide are being tested in prospective phase 2"/>
 <result pre="into the host cells, anti-androgenic agents, such as bicalutamide and" exact="enzalutamide" post="are being tested in prospective phase 2 clinical trials"/>
 <result pre="others. There has been considerable interest in the use of" exact="chloroquine" post="and its less toxic version hydroxychloroquine, because of the"/>
 <result pre="[51]). However, the initial enthusiasm for the potential efficacy of" exact="hydroxychloroquine" post="(alone or in combination with azithromycin) in the treatment"/>
 <result pre="trials [52]. There were no beneficial effects of treatment with" exact="hydroxychloroquine" post="in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) study"/>
 <result pre="(Table 1 ), which randomized 1,542 hospitalized patients to the" exact="hydroxychloroquine" post="and 3,132 patients to the usual care (https://www.recoverytrial.net/results/hydroxychloroquine-results). The"/>
 <result pre="to the usual care (https://www.recoverytrial.net/results/hydroxychloroquine-results). The 28-day mortality in the" exact="hydroxychloroquine" post="group was 25.7% as compared to 23.5% in the"/>
 <result pre="randomized clinical trials are still ongoing to test efficacy of" exact="hydroxychloroquine" post="in the treatment of patients with COVID-19. Table 1"/>
 <result pre="RNA synthesis upon incorporation. Among the nucleoside analogues, remdesivir, an" exact="adenosine" post="analogue, which was originally developed for treatment of Ebola"/>
 <result pre="patients with COVID-19. Preliminary observational data show that treatment with" exact="tocilizumab" post="is associated with improved laboratory and clinical outcomes, including"/>
 <result pre="effects on mortality at 4 weeks between patients treated with" exact="tocilizumab" post="or placebo (NCT04320615). Notable among various interventions is the"/>
 <result pre="requiring respiratory support in the RECOVERY study [69]. Thus far," exact="dexamethasone" post="is the only drug shown to reduce COVID-19 mortality"/>
 <result pre="NEJMoa2019014 53ChorinEDaiMShulmanEWadhwaniLBar-CohenRBarbhaiyaCThe QT interval in patients with COVID-19 treated with" exact="hydroxychloroquine" post="and azithromycinNat Med26202080880932488217 54WangQWuJWangHGaoYLiuQMuAStructural basis for RNA replication by"/>
</results>
